 Home > Active Ingredient News > Immunology News > ARD: IL-12/23 pathway inhibitors ustekinumab or TNFi have comparable persistence and efficacy in patients with psoriatic arthritis

ARD: IL-12/23 pathway inhibitors ustekinumab or TNFi have comparable persistence and efficacy in patients with psoriatic arthritis

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

expensive drug world

7 12 percent

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE : This study evaluated real-world treatment durability and efficacy 1 year after initiation of the IL-12/23 inhibitor ustekinumab or a tumor necrosis factor inhibitor (TNFi) in psoriatic arthritis (PsA.

Objectives This study evaluated real-world treatment durability and efficacy 1 year after initiation of the IL-12/23 inhibitor ustekinumab or a tumor necrosis factor inhibitor (TNFi) in psoriatic arthritis (PsA.

METHODS : PsABio (NCT02627768) was a prospective, observational study of first- to third-line follow-up of ustekinumab or TNFi in patients with Ps.

Methods PsABio (NCT02627768) was a prospective, observational study of first- to third-line follow-up of ustekinumab or TNFi in patients with Ps.

Results At 1 year, overall persistence was similar between the ustekinumab ( n=317/438, 74% ) and TNFi ( n=321/455, 75% ) group.

CONCLUSIONS In the real-world PsABio study, after 1 year of treatment, although the persistence of unadjusted ustekinumab was numerically slightly higher than that of TNFi , the unadjusted efficacy was numerically slightly higher than that of optimal TNF.

Gossec L, Siebert S, Bergmans P , et a.
Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumor necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Stu.
Annals of the Rheumatic Diseases2022; 81: 823-83 , et al Annals of the Rheumatic Diseases81: Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.